A Crossover Study to Evaluate the Efficacy of Simvastatin in Elevating HDL-C Levels in Patients With Type 2 Diabetes (0733-216)(COMPLETED)

Organon

Status and phase: Completed; Phase 3

Conditions: HDL Cholesterol

Treatments: Drug: MK0733 / Duration of Treatment: 18 Weeks; Drug: Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks

Study type: Interventional

Funder types: Industry

Identifiers

NCT00389896

0733-216

2006_536

Details and patient eligibility

About

The purpose of this study is to see how well simvastatin raises HDL levels in patients with Type 2 Diabetes.

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient has stable Type 2 diabetes mellitus at Visit 1.
• Patient meets screening criteria based on Visit 1 lab tests

Exclusion criteria

• Patient is pregnant, breastfeeding, or at risk of becoming pregnant
• Patient has heart disease, uncontrolled high blood pressure, or other significant disease
• Patient is taking prohibited medication(s) and is unable to stop taking them for the duration of the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind